Please assess the completion status of the following clinical trial:

Trial Title: The Artificial Pancreas in Very Young Children With T1D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 1 and 7 years (inclusive) (Luxembourg and Austria)~2. Age between 2 and 7 years (inclusive) (Germany and UK)~3. Type 1 diabetes as defined by WHO for at least 6 months \[WHO definition: 'The aetiological type named type 1 encompasses the majority of cases which are primarily due to beta-cell destruction, and are prone to ketoacidosis. Type 1 includes those cases attributable to an autoimmune process, as well as those with beta-cell destruction for which neither an aetiology nor a pathogenesis is known (idiopathic). It does not include those forms of beta-cell destruction or failure to which specific causes can be assigned (e.g. cystic fibrosis, mitochondrial defects, etc.).'\]~4. Insulin pump user (with or without continuous glucose monitoring or flash glucose monitoring system) for at least 3 months, with subject/carer good knowledge of insulin self-adjustment as judged by the investigator~5. On sensor-augmented pump as standard clinical care (extension phase only)~6. Treated with rapid or ultra-rapid acting insulin analogue~7. Subject/carer is willing to perform regular finger-prick blood glucose monitoring, with at least 2 blood glucose measurements taken every day~8. Screening HbA1c ≤ 11% (97mmol/mol) on analysis from local laboratory~9. Willing to wear glucose sensor~10. Willing to wear closed loop system 24/7 during intervention arm~11. The subject/carer is willing to follow study specific instructions~12. The subject/carer is willing to upload pump and CGM data at regular intervals~Exclusion Criteria:~1. Physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator~2. Untreated coeliac disease or thyroid disease based on local investigations prior to study enrolment~3. Current treatment with drugs known to interfere with glucose metabolism, e.g. systemic corticosteroids~4. Use of closed loop insulin delivery within the past 2 months~5. Known or suspected allergy to insulin~6. Carer's lack of reliable telephone facility for contact~7. Subject/carer's severe visual impairment~8. Subject/carer's severe hearing impairment~9. Medically documented allergy towards the adhesive (glue) of plasters or subject is unable to tolerate tape adhesive in the area of sensor placement~10. Serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) located in parts of the body which could potentially be used for localisation of the glucose sensor)~11. Sickle cell disease, haemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening~12. Plan to receive red blood cell transfusion or erythropoietin over the course of study participation~13. Subject/carer not proficient in English (UK, Germany, Austria, Luxembourg) or German (Germany, Austria, Luxembourg) or French (Luxembourg)~    Additional exclusion criteria - Germany only~14. Known microvascular diabetes complications (retinopathy, renal disease, neuropathy)~15. Eating disorders~16. Psychiatric diseases of the parents that would possibly interfere with the ability to comply to study procedures~17. Major needle phobia that would complicate to wear pump catheter and sensor~18. Congenital malformations that would interfere with diabetes treatment (e.g. congenital heart malformations, lung diseases, renal malformations)~19. Growth hormone deficiency~20. Combined Hypopituitarism~21. Down Syndrome (high risk for comorbidity with coeliac disease, autoimmune thyroiditis)~22. Cancer under treatment~23. Current participation in other interventional clinical trials

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Automated closed loop insulin delivery (intervention arm) (Type: EXPERIMENTAL): Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.~Intervention: Device: CamAPS FX
- Sensor augmented pump therapy (control arm) (Type: ACTIVE_COMPARATOR): Sensor augmented pump therapy over 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete